The global immunoglobulins market is set to grow impressively at a CAGR of 7.0% during the forecast period. The market is poised to reach a valuation of US$ 20.7 Bn by 2026-end.
Rising adoption of immunoglobulins for the treatment of critical immunological are the driving the market
The global immunoglobulins market is set to grow impressively at a CAGR of 7.0% during the forecast period (2020-2026). The market is poised to reach a valuation of US$ 20.7 Bn by 2026-end. Upsurge in immunological diseases has prompted individuals to seek advanced medical treatment, thus augmenting the immunoglobulins market share.
The Immune Deficiency Foundation (IDF) estimates that approximately 83 people per 100,000 in North America suffer from primary immunodeficiency, leading to the prevalence of such diseases. In response, off-label indications, intravenous and subcutaneous immunoglobulins have risen considerably. The rising geriatric population pool shall also steer market growth. The ongoing COVID-19 pandemic is anticipated to provide leverage to the immunoglobulins market as healthcare providers are increasingly researching ways to apply immunoglobulins to treat the disease.
Request a report sample to gain compressive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=4788
Key Takeaways of Global Immunoglobulins Market Study:
- By application, the neurology segment is forecast to hold a significant portion of the global immunoglobulins market (~2/5th). The rising prevalence of neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy are anticipated to leverage the segment’s growth.
- By administration route, the intravenous segment (IVIG) is anticipated to capture more than three-fourth of the global immunoglobulin market, expanding healthily at a CAGR of 7.0%. This is due to increased approval of products such as Carimune NF, Flebogamma DIF and GAMMAGARD S/D to treat major chronic rare diseases. Simultaneously, the subcutaneous segment is anticipated to expand healthily at a CAGR of 8.3% during the forecast period.
- With respect to end-use, the homecare segment is set to surpass all others during the forecast period. Better supervision of patients while undergoing infusions is a key driver behind the segment’s expansion. The home care segment is set to register a staggering CAGR of 8.3%, capturing almost two-fifths of the overall immunoglobulins market.
- North America is forecast to dominate the global immunoglobulins market across the forecast period. The rising prevalence of immunological and neurological disorders, adoption of IVIG products as well as significant reimbursement coverage shall leverage market share. The region shall account for nearly half of the global immunoglobulins market, expanding at a CAGR of 7.1%.
- Asia-Pacific is anticipated to grow the fastest, at a CAGR of 8.5% throughout the forecast period. Expanding healthcare markets, untapped potential, acceptance of immunoglobulins products in developing countries and increasing geriatric population are key drivers expected to leverage the region’s growth prospects.
“Several key players have made credible investments in research and development programs for IVIG, SCIG and IMIG applications. Promising results in novel clinical applications are poised to generate lucrative opportunities for the global immunoglobulins market,” concludes a Fact.MR analyst.
To gain in-depth insights on Immunoglobulins Market request methodology at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=4788
Global Immunoglobulins Market: Competitive Landscape
The global immunoglobulins consist of the following key players such as Grifols S.A, Shire, CSL Behring, Octapharma, Kedrion Biopharma Inc., China Biologic Products Holdings, Inc., Biotest AG, Sanquin and LFB SA. Most of these companies concentrate on molecular immunoglobulins indications and subsequent development of pipeline products.
Grifols S.A, for instance, manufactures Gamunex C and Flebogamma Intravenous immunoglobulin products. Gamunex C is a sterilized solution made from the human plasma which contains antibodies to treat primary immunodeficiency. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency and Wiskott - Aldrich syndrome.
Likewise, CSL Behring produces subcutaneous immunoglobulin products such as Privigen, Evogam and Beriglobin P. Berigloin P which are presented in the form of an injection containing excipients of glycine, sodium chloride, hydrochloric acid or sodium hydroxide and water.
- Grifols S.A
- Shire and CSL Behring.
- Octapharma
- Kedrion Biopharma Inc.
- China Biologic Products Holdings Inc.
- Biotest AG
- Sanquin
- LFB SA.
More Insights on the Global Immunoglobulins Sales Outlook
Fact.MR has studied the global immunoglobulins market with detailed segmentation on the basis of Application, Route of Administration, End-user and key regions.
Application
- Neurology
- Immunology
- Hematology
- Others
Route of Administration
- Intravenous
- Subcutaneous
- Intramuscular
End-user
- Hospitals
- Clinics
- Homecare
Key Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Report Benefits & Key Questions Answered
- Immunoglobulins Historical Volume Analysis: The comprehensive analysis by Fact.MR highlights the emerging trends along with major drivers, restraints, challenges, and opportunities.
- Immunoglobulins Sales Outlook: A comprehensive study conducted by Fact.MR inspects vital micro and marco-economic indexes and offers cognizance on their impact on the sales of immunoglobulins during the assessment period. As per the study, the sale of immunoglobulins will total US$ 20.7 Bn, rising at a CAGR of nearly 7% through 2026.
- Immunoglobulins Market Trend Analysis: The report offers a detailed analysis of manufacturing trends in the immunoglobulins market. Reviting insights on how medical companies craft innovative strategies to strengthen their consumer base
- Immunoglobulins Market Structure Analysis: The study on market structure analysis provides extensive data about market concentration, level of competition, and tier analysis of the key players in the immunoglobulins market along with their insights on their global footprint based on region, country, segment, and product portfolio.
Explore Fact.MR’s Coverage on the Healthcare Domain –
Cell-Free Fetal DNA Testing Market: Cell-free fetal DNA testing is a screening test which is used to determine chromosomal abnormalities in infants. With the advancement in the technology new techniques such as cell-free fetal DNA testing have been evolved which are non- invasive and require venipuncture by which they collect the mothers blood.
DNA Polymerase Market: DNA polymerase is a unique Pyrococcus-like proofreading enzyme fused to the Sso7d dsDNA-binding protein to create a thermostable fusion polymerase that accurately amplifies long products from a variety of DNA templates. High-fidelity PCR enzymes are used for applications requiring high accuracy during DNA amplification such as sequencing, cloning, or mutagenesis.
Home DNA Testing Market: According to latest research by Fact.MR, home DNA testing market is set to witness steady growth during 2021-2031. Demand for home DNA testing market will witness steady recovery in short-term, with optimistic growth outlook in the long-run.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000’s trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com